JHOP - October 2023 Vol 13, No 5

Editorial

Are We Ready for Same-Day Pegfilgrastim and Chemotherapy?

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA Clinical Professor Emeritus, University of California, San Francisco; Professor Emeritus, Touro University–California, Mare Island, Vallejo, CA

Original Article

Original Article

Tolerance of Oral Targeted Agents in Patients With Advanced or Metastatic RCC With and Without Renal Impairment

Bradley Mayer, PharmD, BCOP; Emma Carroll, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP; Felicia Zook, PharmD, BCOP

Original Article

Clinical, Laboratory, and Genetic Profiles and Outcomes of Patients With aHUS and Restrictive Use of Eculizumab: A Single-Center Experience

Fnu Amisha, MD; Manojna Konda, MD; Paras Malik, MD; Brad Fugere, BGS; Arya Mariam Roy, MD; Appalanaidu Sasapu, MD

Original Article

Evaluation of Same-Day Versus Next-Day Administration of Pegfilgrastim in Patients With Breast Cancer

Michael P. Weise Jr, PharmD, BCOP; Vincent Cascone, PharmD, BCOP; Huong Tran, PharmD; Grace Martin, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; Guangyi Gao, MS, PhD; Qamar Khan, MD

Practical Issues in Pharmacy Management

Practical Issues in Pharmacy Management

Enhancing Pharmacovigilance Methodologies in Patients With Cancer at Infusion Centers

Joy Leonard, PharmD; Michael Goldenhorn, PharmD, MBA; Christopher Keeys, PharmD, BCPS; Sabeen Ali, PharmD

Practical Issues in Pharmacy Management

Clinical Role of Oncology Pharmacy Specialists in Oral Oncolytic Management in the Outpatient Hematology Clinic Setting

Lilia Davenport, PharmD, BCPS; Monica Tadros, PharmD, BCPS, BCOP; Tiba Al Sagheer, PharmD, BCOP, BCACP; Sharmeen Roy, PharmD, BCPS; Muni Rubens, MD, PhD; Alga Ramos Morales, PharmD, MS, MBA, BCPS, BCOP, CSSGB; Moe Shwin, PharmD, BCOP

FDA Oncology Update

FDA Oncology Update

Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion

FDA Oncology Update

FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation

FDA Oncology Update

FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Oncology Update

Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases

FDA Oncology Update

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.